- Dosage: Insulin 300 iu /3ml
- Volume: 3 ml cartridge
- Packaging: Sterile 3 ml cartridge for injection, 1 cartridge/tray*1 box
- Shelf Life: 36months
Package:
Product Description
Mixed Protamine Human Insulin 30R: What the Published Guidance Says
Human and analogue insulins alongside the oral hypoglycaemics and cardiorenal-metabolic agents added to the WHO Model List in its September 2025 revision.
Mixed Protamine Human Insulin 30R is specified against its own monograph, pack size and market registration, so the guidance below is worth reading together with the Diabetes & Insulin range overview.
- The Model List details the insulin presentations and strengths Section 18.5.1 of the 24th WHO Model List (2025) lists human short-acting insulin as an injection solution of 40 IU/mL or 100 IU/mL in 10 mL vials and 100 IU/mL in 3 mL cartridges or pre-filled pens. Human intermediate-acting insulin is listed as an injection suspension in the same strengths, as compound insulin zinc suspension or isophane insulin. Long-acting and rapid-acting analogues are listed with glargine, degludec and detemir named among the therapeutic alternatives — a footnote notes that quality-assured biosimilars are included. WHO eEML — Medicines for diabetes
- The scale of the access problem WHO reports that more than 800 million people were living with diabetes in 2022, with half going untreated, and that more than one billion people worldwide are affected by obesity with rates rising fastest in low- and middle-income countries. WHO — Essential medicines list updated to include key cancer and diabetes treatments (5 Sep 2025)
- September 2025 added the GLP-1 class WHO added the GLP-1 receptor agonists semaglutide, dulaglutide and liraglutide, and the dual GLP-1/GIP agonist tirzepatide, for adults with type 2 diabetes where cardiovascular disease or chronic kidney disease is established and obesity is present (BMI ≥ 30 kg/m²). WHO — Essential medicines list updated to include key cancer and diabetes treatments (5 Sep 2025)
These points are quoted because they shape how Mixed Protamine Human Insulin 30R is specified, labelled and purchased — including strength selection, pack size and the artwork wording. Confirm each one against the approved product information in your market before finalising a purchase order.
Mixed Protamine Human Insulin 30R — Supply Parameters
| Product Name | Mixed Protamine Human Insulin 30R (30% Regular + 70% Isophane/NPH Human Insulin Mixture) |
| Specification | 100 IU/mL; 30% soluble (regular) human insulin + 70% protamine isophane (NPH) human insulin; supplied as 3mL cartridge (300 IU) or 10mL vial (1000 IU) |
| Dosage Form | Sterile Suspension for Subcutaneous Injection (SC) |
| Active Ingredient | Human Insulin (recombinant DNA origin) — 30% regular (soluble) + 70% isophane (NPH) mixture |
| Pharmacological Class | Antidiabetic Agent / Intermediate-Acting Insulin (Mixed/Biphasic Insulin) |
| Route of Administration | Subcutaneous (SC) injection only. Do NOT administer intravenously (IV). Administered by the patient or caregiver, typically before meals (30 minutes before breakfast and/or dinner). |
| Storage | Refrigerate at 2°C to 8°C. Do not freeze. Protect from light and heat. In-use product may be kept below 25°C (not in refrigerator) for up to 28 days (per label). |
| Therapeutic group | Diabetes & Insulin — Diabetes & Insulin |
| Manufacturer | Sinophare Bio-technology Co., Ltd. (GMP, China) |
| Documentation supplied | COA, HPLC/GC data, stability data, dossier package |
The same therapeutic range is supplied in several presentations, so one purchase order can cover a mixed requirement: Insulin Glargine Injection 100IU/mL 3ml Cartridge, Isophane Protamine Human Insulin 100IU/mL 3ml, Human Insulin Injection 3ml 300IU Cartridge & 10ml 1000IU Vial, Dapagliflozin 10mg Tablets, Canagliflozin 300mg Tablets, Empagliflozin 25mg Tablets, Ertugliflozin 15mg Tablets, Finerenone 20mg Tablets.
Quality Control, Pharmacopoeial Standards & Documentation
Products are manufactured and tested against USP, EP, BP and CP monographs, with incoming raw-material inspection, in-process monitoring and full finished-product testing.
Mixed Protamine Human Insulin 30R is released against the pharmacopoeial monograph named on your order (USP, EP, BP or CP). Where no monograph exists for the exact presentation, the specification is agreed with you in writing before manufacture and is attached to the certificate of analysis.
Standardised GMP production workshops with an independent R&D laboratory and a complete quality-inspection centre.
A typical release panel for this presentation covers:
- Testing for description and identification
- Testing for assay of the active substance
- Testing for related substances and impurities
- Testing for dissolution or release profile (solid oral forms)
- Testing for uniformity of dosage units
- Testing for water content and pH where applicable
COA, HPLC and GC data, DMF and dossier packages, plus registration support documents for national marketing-authorisation filings.
Packaging, Labelling & Export
- Pack size: 3mL cartridges (300 IU) for use with insulin pens, or 10mL vials (1000 IU); supplied in boxes of 5 cartridges or 1 vial. Non-standard pack sizes can be quoted against your artwork.
- Storage: Refrigerate at 2°C to 8°C. Do not freeze. Protect from light and heat. In-use product may be kept below 25°C (not in refrigerator) for up to 28 days (per label)..
- Shelf life: 24 months (unopened, refrigerated). Stability data for the marketed pack is included in the dossier.
- Labelling: artwork can be produced in English, Arabic, French, Russian and Spanish, with your own brand and language mix, subject to the labelling rules of the destination market.
- Export: GMP certificate, COA, certificate of origin, packing list and, where required, the free-sale or marketing authorisation certificate from the country of manufacture.
Registration, Dossier & Tender Support
Sinophare Bio-technology Co., Ltd. holds DML Number Jin20160068 (medicines) and Jin20160069 (paracetamol API).. That registration identifies the legal manufacturer on the certificate of analysis, the GMP certificate and the documents filed with your national medicines authority.
- CTD dossier modules 1–5 in editable and PDF form, with the finished-product and API sections cross-referenced.
- Site Master File and GMP certificate for the manufacturing workshops.
- Method validation, stability protocol and the shelf-life justification for the marketed pack.
- Answers to authority questions during assessment, handled by the regulatory contact who prepared the file.
- Tender and framework documentation, including pre-qualification questionnaires and sample logistics.
This page describes Mixed Protamine Human Insulin 30R as a product of the medicines for diabetes listed in the WHO Model List family. A WHO or national listing is a supply-context fact, not an approval in your market; marketing authorisation remains specific to each country.
Frequently Asked Questions
What pack size is available for Mixed Protamine Human Insulin 30R?
The reference pack is 3mL cartridges (300 IU) for use with insulin pens, or 10mL vials (1000 IU); supplied in boxes of 5 cartridges or 1 vial. Non-standard blister, bottle and carton configurations are quoted against your artwork, matched to the stability data already held for the presentation.
What documentation comes with a shipment of Mixed Protamine Human Insulin 30R?
Each batch ships with a certificate of analysis covering description, identification, assay and related substances, plus stability data for the marketed pack and the GMP certificate of the manufacturing site. Shelf life: 24 months.
Does the batch documentation for Mixed Protamine Human Insulin 30R support a registration filing?
Each batch ships with a certificate of analysis covering description, identification, assay and related substances, plus stability data for the marketed pack and the GMP certificate of the manufacturing site. Shelf life: 24 months. The full CTD dossier and the authority assessment file are supplied as part of a registration order; routine shipments carry the COA and stability data only.
Do you supply human insulin as well as analogues?
Yes. We supply human short-acting, isophane and premixed 30/70 protamine human insulin, and insulin glargine. The Model List notes that quality-assured biosimilars are included in its analogue listings.
Which SGLT2 inhibitors do you supply?
Empagliflozin, dapagliflozin, canagliflozin and ertugliflozin in tablet form. Empagliflozin is the molecule specifically listed in section 18.5.2 of the Model List, with canagliflozin and dapagliflozin named as therapeutic equivalents.
Related Diabetes & Insulin Products
- Insulin Glargine Injection 100IU/mL 3ml Cartridge — 100IU
- Isophane Protamine Human Insulin 100IU/mL 3ml — 100IU
- Human Insulin Injection 3ml 300IU Cartridge & 10ml 1000IU Vial — 100IU
- Dapagliflozin 10mg Tablets — 10mg
- Canagliflozin 300mg Tablets — 300mg
- Empagliflozin 25mg Tablets — 25mg
Browse the full Diabetes & Insulin range; all Injectables; the complete product catalogue.
Request a Quotation for Mixed Protamine Human Insulin 30R
Send the specification, pack size, quantity and destination market for Mixed Protamine Human Insulin 30R 100IU and we will confirm availability, lead time and documentation. Tender quantities and registration samples are handled on the same quotation.
Sources & Regulatory Notes
- WHO eEML — Medicines for diabetes
- WHO — Essential medicines list updated to include key cancer and diabetes treatments (5 Sep 2025)
Reference information only. The published guidance summarised on this page is quoted for professional and regulatory-context purposes and does not constitute medical advice, a prescribing recommendation or a promotion of any product for a particular indication. Prescribing decisions must follow the approved product information and national treatment guidelines in the market of use.
